MEI Pharma To Present At Cowen Health Care And ROTH Conferences

       MEI Pharma To Present At Cowen Health Care And ROTH Conferences

Live Webcasts from Boston on March 4th and Laguna Niguel on March 10th

PR Newswire

SAN DIEGO, Feb. 25, 2014

SAN DIEGO, Feb. 25, 2014 /PRNewswire/ --MEI Pharma, Inc. (Nasdaq: MEIP), an
oncology company focused on the clinical development of novel therapies for
cancer, announced today that Daniel P. Gold, Ph.D., President and Chief
Executive Officer, will present at two upcoming investor conferences:

  oThe Cowen and Company 34^th Annual Health Care Conference on Tuesday,
    March 4, 2014 at 8:40 a.m. Eastern time from the Boston Marriott Copley
    Place; and
  oThe 26^th Annual ROTH Conference on Monday, March 10, 2014 at 2:30 p.m.
    Pacific time from the Ritz-Carlton, Laguna Niguel.

(Logo:http://photos.prnewswire.com/prnh/20120628/LA32362LOGO)

Live webcasts of the presentations can be accessed at
www.meipharma.com.Replays will be available approximately one hour after the
presentations.

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused
on the clinical development of novel therapies for cancer. The Company's lead
drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor
currently being developed for myelodysplastic syndrome (MDS) and acute myeloid
leukemia (AML). Results from a pilot Phase II clinical trial of Pracinostat in
combination with Vidaza^® (azacitidine) in patients with advanced MDS showed
an overall response rate of 90% (nine of 10). Data from three ongoing Phase II
clinical trials of Pracinostat are expected by the end of 2014. MEI Pharma is
also developing ME-344, a mitochondrial inhibitor that has shown preliminary
evidence of single-agent activity in a first-in-human clinical study in
patients with refractory solid tumors, including eight of 21 evaluable
patients (38%) who achieved stable disease or better. In September 2013, the
Company further expanded its pipeline of drug candidates with the acquisition
of PWT143, a highly selective PI3-kinase delta inhibitor. For more
information, go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated
in clinical trials and approved by the FDA as being safe and effective for the
intended use. Statements included in this press release that are not
historical in nature are "forward-looking statements" within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ materially
from those contained in the forward-looking statements, which are based on
management's current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in clinical trial
results; our inability to maintain or enter into, and the risks resulting from
our dependence upon, collaboration or contractual arrangements necessary for
the development, manufacture, commercialization, marketing, sales and
distribution of any products; competitive factors; our inability to protect
our patents or proprietary rights and obtain necessary rights to third party
patents and intellectual property to operate our business; our inability to
operate our business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to gain
market acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice;
and one-time events. We do not intend to update any of these factors or to
publicly announce the results of any revisions to these forward-looking
statements.

SOURCE MEI Pharma, Inc.

Website: http://www.meipharma.com
Contact: Pete De Spain, Sr. Director, Investor Relations & Corporate
Communications, (858) 792-3729, pdespain@meipharma.com
 
Press spacebar to pause and continue. Press esc to stop.